



**WHISTLE BLOWER POLICY**  
**JAGSONPAL PHARMACEUTICALS LIMITED**

<b>1.</b>	<b>PREFACE</b>
<b>a.</b>	<p>The Company believes in the conduct of the affairs of its constituents in a fair and transparent manner by adopting highest standards of professionalism, honesty, integrity and ethical behaviour. Towards this end, the Company has adopted the Jagsonpal Pharmaceuticals Limited Code of Conduct (“the Code”), which lays down the principles and standards that should govern the actions of the Company and its employees. Any actual or potential violation of the Code, howsoever insignificant or perceived as such, would be a matter of serious concern for the Company. The role of the employees in pointing out such violations of the Code cannot be undermined. There is a provision under the Code requiring employees to report violations, which states:</p> <p>“Compliance Officer shall report breach of this code, if any, which comes to his notice from any employee to the: (a) Board in case of all Board members and (b) Managing Director in case of Senior Management Personnel.”</p>
<b>b.</b>	<p>The Companies Act, 2013 read with Regulation 4 (2) (d) (iv) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 (SEBI LODR) provides for a mandatory requirement to establish a vigil mechanism /whistle blower policy enabling stakeholders, including individual employees and their representative bodies, to freely communicate their concerns about illegal or unethical practices.</p>
<b>c.</b>	<p>Accordingly, this Whistle Blower Policy (“the Policy”) has been formulated with a view to provide a mechanism for Employees and other Stakeholders to approach the Ethics Counsellor or the Chairman of the Audit Committee of the Company.</p>
<b>2</b>	<b>DEFINITIONS</b>
	<p>The definitions of some of the key terms used in this Policy are given below. Capitalized terms not defined herein shall have the meaning assigned to them under the Code</p>
<b>a.</b>	<p><b>“Audit Committee”</b> means the Audit Committee constituted by the Board of Directors of the Company in accordance with Section 177 of the Companies Act, 2013 read with Regulation 18 of SEBI LODR.</p>
<b>b.</b>	<p><b>“Employee”</b> means every employee of the Company (whether working in India or abroad), including the Directors of the Company</p>
<b>c.</b>	<p><b>“Code”</b> means the Jagsonpal Pharmaceuticals limited Code of Conduct</p>
<b>d.</b>	<p><b>“Investigators”</b> mean those persons authorized, appointed, consulted or approached by the Ethics Counsellor or the Chairman of the Audit Committee and includes the auditors of the Company.</p>

e.	<p><b>“Protected Disclosure”</b> means any communication made in good faith that discloses or demonstrates information that may evidence unethical or improper activity.</p>
f.	<p><b>“Stakeholders”</b> means and includes vendors, suppliers, lenders, customers, business associates, trainee and others with whom the Company has any financial or commercial dealings.</p>
	<p><b>“Subject”</b> means a person against or in relation to whom a Protected Disclosure has been made or evidence gathered during the course of an investigation</p>
g.	<p><b>“Unpublished Price Sensitive Information”</b> (UPSI) means any information, relating to the Company or its securities, directly or indirectly, that is not generally available which upon becoming generally available, is likely to materially affect the price of the securities and shall, ordinarily including but not restricted to, information relating to the following:</p> <ul style="list-style-type: none"> <li>• financial results;</li> <li>• dividends;</li> <li>• change in capital structure;</li> <li>• mergers, de-mergers, acquisitions, delisting, disposals and expansion of business and such other transactions;</li> <li>• change in key managerial personnel; and</li> <li>• such other information as communicated by the Compliance Officer on need basis</li> </ul>
h.	<p><b>“Whistle Blower”</b> means a Director or an Employee making a Protected Disclosure under this Policy.</p>
i.	<p><b>“Ethics Counsellor”</b> means an officer who is/are nominated/ appointed to conduct detailed investigation of the disclosure received from the whistleblower and recommend disciplinary action.</p>
<b>3.</b>	<b>SCOPE</b>
a.	<p>This Policy is an extension of the Jagsonpal Pharmaceuticals Limited Code of Conduct. The Whistle Blower’s role is that of a reporting party with reliable information. They are not required or expected to act as investigators or finders of facts, nor would they determine the appropriate corrective or remedial action that may be warranted in a given case</p>
b.	<p>Whistle Blowers should not act on their own in conducting any investigative activities, nor do they have a right to participate in any investigative activities other than as requested by the Ethics Counsellor or Chairman of the Audit Committee or the Investigators.</p>
c.	<p>The employees of the Company can also report instances of leak of Unpublished Price Sensitive Information (UPSI) under the mechanism provided in the Policy</p> <p>Protected Disclosure will be appropriately dealt with by the Ethics Counsellor or Chairman of the Audit Committee, as the case may be</p>



<b>4</b>	<b>ELIGIBILITY</b>
	All Employees, Directors and stakeholders of the Company are eligible to make Protected Disclosures under the Policy. The Protected Disclosures may be in relation to matters concerning the Company.
<b>5</b>	<b>DISQUALIFICATIONS</b>
<b>a</b>	While it will be ensured that genuine Whistle Blowers are accorded complete protection from any kind of unfair treatment as herein set out, any abuse of this protection will warrant disciplinary action.
<b>b</b>	Protection under this Policy would not mean protection from disciplinary action arising out of false or bogus allegations made by a Whistle Blower knowing it to be false or bogus or with a mala fide intention.
<b>c</b>	Whistle Blowers, who make any Protected Disclosures, which have been subsequently found to be mala fide or malicious or Whistle Blowers who make 3 or more Protected Disclosures, which have been subsequently found to be frivolous, baseless or reported otherwise than in good faith, will be disqualified from reporting further Protected Disclosures under this Policy.
<b>6</b>	<b>PROCEDURE</b>
<b>a</b>	All Protected Disclosures concerning financial/accounting matters should be addressed to the Ethics Counsellor or the Chairman of the Audit Committee of the Company for investigation
<b>b</b>	In respect of all other Protected Disclosures, those concerning the employees at the levels of Vice Presidents and above should be addressed to the Chairman of the Audit Committee of the Company and those concerning other employees should be addressed to the Ethics Counsellor of the Company.
<b>c</b>	<p>The contact details of the Chairman of the Audit Committee are as under:</p> <p>Chairman of Audit Committee Mr. Debasis Bikash Nandy Email Id: <a href="mailto:Chairmanofauditcommittee@jagsonpal.com">Chairmanofauditcommittee@jagsonpal.com</a></p> <p>The contact details of the Ethics Counsellor are as under:</p> <p>Mr. Bharat Chugh General Manager -HR Jagsonpal Pharmaceuticals Limited 412-415, Nimai Tower 3<sup>rd</sup> Floor, Phase – IV Udyog Vihar Gurugram – 122 015 Mobile: +91 7617555333 Email Id: <a href="mailto:bharat.chugh@jagsonpal.com">bharat.chugh@jagsonpal.com</a></p> <p>If a protected disclosure is received by any executive of the Company other than Chairman of Audit Committee or the Ethics Counsellor, the same should be forwarded to the Company's ethics Counsellor or the Chairman of the Audit Committee for further appropriate action.</p>

	Appropriate care must be taken to keep the identity of the Whistle Blower confidential.
<b>d</b>	Protected Disclosures should preferably be reported in writing so as to ensure a clear understanding of the issues raised and should either be typed or written in a legible handwriting in English, Punjabi, Hindi or in the regional language of the place of employment of the Whistle Blower. Alternatively, Protected Disclosures can also be reported orally, which will normally be documented by the Ethics Counsellor / Chairman of the Audit Committee accessing the voice mail by a written transcription of the oral report
<b>e</b>	The Protected Disclosure should be forwarded under a covering letter which shall bear the identity of the Whistle Blower. The Chairman of the Audit Committee / Ethics Counsellor, as the case may be shall detach the covering letter and forward only the Protected Disclosure to the Investigators for investigation
<b>f</b>	Protected Disclosures should be factual and not speculative or in the nature of a conclusion, and should contain as much specific information as possible to allow for proper assessment of the nature and extent of the concern.
<b>g</b>	For the purpose of providing protection to the Whistle Blower, the Whistle Blower should disclose his/her identity in the covering letter forwarding such Protected Disclosure.

<b>7</b>	<b>INVESTIGATION</b>
<b>a</b>	All Protected Disclosures reported under this Policy will be thoroughly investigated by the Ethics Counsellor / Chairman of the Audit Committee of the Company who will investigate / oversee the investigations under the authorization of the Audit Committee.
<b>b</b>	The Ethics Counsellor / Chairman of the Audit Committee may at his discretion, consider involving any Investigators for the purpose of investigation
<b>c</b>	The decision to conduct an investigation taken by the Ethics Counsellor /Chairman of the Audit Committee is by itself not an accusation and is to be treated as a neutral fact- finding process. The outcome of the investigation may not support the conclusion of the Whistle Blower that an improper or unethical act was committed.
<b>d</b>	The identity of a Subject and the Whistle Blower will be kept confidential to the extent possible given the legitimate needs of law and the investigation.
<b>e</b>	Subjects will normally be informed of the allegations at the outset of a formal investigation and have opportunities for providing their inputs during the investigation
<b>f</b>	Subjects shall have a duty to co-operate with the Ethics Counsellor /Chairman of the Audit Committee or any of the Investigators during investigation to the extent that such co-operation will not compromise self-incrimination protections available under the applicable laws.

<b>g</b>	Subjects have a right to consult with a person or persons of their choice, other than the Ethics Counsellor / Investigators and/or members of the Audit Committee and/or the Whistle Blower. Subjects shall be free at any time to engage counsel at their own cost to represent them in the investigation proceedings
<b>h</b>	Subjects have a responsibility not to interfere with the investigation. Evidence shall not be withheld, destroyed or tampered with, and witnesses shall not be influenced, coached, threatened or intimidated by the Subjects
<b>i</b>	Unless there are compelling reasons not to do so, Subjects will be given the opportunity to respond to material findings contained in an investigation report. No allegation of wrongdoing against a Subject shall be considered as maintainable unless there is good evidence in support of the allegation.
<b>j</b>	Subjects have a right to be informed of the outcome of the investigation. If allegations are not sustained, the Subject should be consulted as to whether public disclosure of the investigation results would be in the best interest of the Subject and the Company.
<b>k</b>	The investigation shall be completed normally within 45 days of the receipt of the Protected Disclosure.

<b>8</b>	<b>PROTECTION</b>
<b>a</b>	No unfair treatment will be meted out to a Whistle Blower by virtue of his/her having reported a Protected Disclosure under this Policy. The Company, as a policy, condemns any kind of discrimination, harassment, victimization or any other unfair employment practice being adopted against Whistle Blowers. Complete protection will, therefore, be given to Whistle Blowers against any unfair practice like retaliation, threat or intimidation of termination the like including any termination/suspension of service, disciplinary action, transfer, demotion, refusal of promotion, or direct or indirect use of authority to obstruct the Whistle Blowers right to continue to perform his duties/functions including making further Protected Disclosure. The Company will take steps to minimize difficulties, which the Whistle Blower may experience as a result of making the Protected Disclosure. Thus, if the Whistle Blower is required to give evidence in criminal or disciplinary proceedings, the Company will arrange for the Whistle Blower to receive advice about the procedure, etc.
<b>b</b>	A Whistle Blower may report any violation of the above clause to the Chairman of the Audit Committee, who shall investigate into the same and recommend suitable action to the management.
<b>c</b>	The identity of the Whistle Blower shall be kept confidential to the extent possible and permitted under law.
<b>d</b>	Any other Employee assisting in the said investigation shall also be protected to the same extent as the Whistle Blower.

<b>9</b>	<b>INVESTIGATORS</b>
<b>a</b>	Investigators are required to conduct a process towards fact-finding and analysis. Investigators shall derive their authority and access rights from the Ethics Counsellor / Audit Committee when acting within the course and scope of their investigation.
<b>b</b>	Technical and other resources may be drawn upon as necessary to augment the investigation. All Investigators shall be independent and unbiased both in fact and as perceived. Investigators have a duty of fairness, objectivity, thoroughness, ethical behavior, and observance of legal and professional standards.
<b>c</b>	Investigations will be launched only after a preliminary review by the Chairman of the Audit Committee or the Ethics Counsellor, as the case may be, which establishes that <ul style="list-style-type: none"> <li>i. the alleged act constitutes an improper or unethical activity or conduct, and</li> <li>ii. the allegation is supported by information specific enough to be investigated or in cases where the allegation is not supported by specific information, it is felt that the concerned matter is worthy of management review. Provided that such investigation should not be undertaken as an investigation of an improper or unethical activity or conduct</li> </ul>
<b>10</b>	<b>DECISION</b>
	If an investigation leads the Ethics Counsellor / Chairman of the Audit Committee to conclude that an improper or unethical act has been committed, the Ethics Counsellor / Chairman of the Audit Committee shall recommend to the management of the Company to take such disciplinary or corrective action as the Ethics Counsellor / Chairman of the Audit Committee may deems fit. It is clarified that any disciplinary or corrective action initiated against the Subject as a result of the findings of an investigation pursuant to this Policy shall adhere to the applicable personnel or staff conduct and disciplinary procedures
<b>11</b>	<b>REPORTING</b>
	The Ethics Counsellor shall submit a report to the Chairman of the Audit Committee on a regular basis about all Protected Disclosures referred to him/her since the last report together with the results of investigations, if any.
<b>12</b>	<b>RETENTION OF DOCUMENTS</b>
	All Protected Disclosures in writing or documented along with the results of investigation relating thereto shall be retained by the Company for a minimum period of three years.
<b>13</b>	<b>AMENDMENT</b>
	The Company reserves its right to amend or modify this Policy in whole or in part, at any time without assigning any reason whatsoever. However, no such amendment or modification will be binding on the Employees unless the same is notified to the Employees in writing.



<b>Version No.</b>	<b>Date of Approval</b>	<b>Effective from</b>
Version 1		
Version 2	May 23, 2023	May 23, 2023
Version 3	May 20, 2024	May 20, 2024
Version 4	May 06, 2025	May 06, 2025
Version 5	July 26, 2025	July 26, 2025